P109-32 Concurrent Genomic Alterations in ALK-Rearranged Non-Small Cell Lung Cancer Patients

Background: Recent progress in genomic analysis using next-generation sequencing (NGS) has enabled the comprehensive detection of targetable alterations in non-small cell lung cancer (NSCLC) patients. As the detection of ALK gene fusions is being established by NGS, identification of concurrent alterations will lead to better characterization of the molecular landscape of ALK-rearranged patients. Conclusion: We have studied the presence of ALK fusion genes with a novel NGS panel that showed excellent correlation with standard techniques. ALK fusions can be interpreted as early strong drivers to carcinogenesis due to the low frequency of concurrent alterations. It remains to determine the clinical impact of these alterations in larger series. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1061

Authors: S. Clavé, M. Salido, J. Gibert, M. Hardy-Werbin, E. Weingartner, J. Hernandez, D. Nichol, P. Rocha, X. Riera, R. Blanco, J. Bosch-Barrera, Á. Taus, L. Pijuan, B. Bellosillo, E. Arriola

Conference PaperKirk SmithOctober 1, 2019ALK rearrangement, Concurrent alterations, Next-generation sequencing

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns

Background: Detection of ALK and ROS1 gene rearrangements in non–small-cell lung cancer is required for directing patient care. Although fluorescence in situ hybridization (FISH) and immunohistochemistry have been established as gold standard methods, next-generation sequencing (NGS) platforms are called to be at least equally successful. Comparison of these methods for translation into daily use is currently under investigation. Conclusion: Our data support that the identification of 3' isolated signal FISH pattern in ALK and ROS1 cases might suggest a false-positive result. NGS seems a reliable technique to assess ALK and ROS1 rearrangements, offering the advantage over immunohistochemistry of detecting other molecular alterations with potential therapeutic implications. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2019.02.008

Authors: Sergi Clavé, Natalia Rodon, Lara Pijuan, Olga Díaz, Marta Lorenzo, Pedro Rocha, Álvaro Taus, Remei Blanco, Joaquim Bosch-Barrera, Noemí Reguart, Noelia de la Torre, Glòria Oliveras, Blanca Espinet, Beatriz Bellosillo, Xavier Puig, Edurne Arriola, Marta Salido

Case StudyKirk SmithFebruary 26, 2019Concurrent alterations, Fluorescence in situ hybridization (FISH), Gene copy number variations, Resistance mutations, Targeted therapies